A Phase I/II Study of REGN5093-M114 in People with Advanced Non-Small Cell Lung Cancer

Share
Print

Full Title

A Phase 1/2 Study of REGN5093-M114 (METXMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer

Purpose

The purpose of this study is to find the highest dose of the investigational drug REGN5093-M114 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) that is inoperable or cannot be successfully treated with standard therapies and makes high levels of a protein called MET. This protein can cause cancer to grow and spread.

REGN5093-M114 is designed to attach to cancer cells that make the MET protein and deliver a chemotherapy drug directly to those cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced NSCLC that is inoperable or cannot be successfully treated with standard therapies and makes high levels of a protein called MET.
  • Patients must recover from the serious side effects of prior therapies before receiving REGN5093-M114.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Alexander Drilon at 646-608-3758.

Protocol

21-395

Phase

I/II

Investigator

Co-Investigators